ArticleFrontiers in medicine2026
Development and internal validation of the elderly COPD diagnostic score (ECDS): a multidimensional diagnostic tool for moderate-to-severe chronic obstructive pulmonary disease.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate diagnosis of chronic obstructive pulmonary disease (COPD) among elderly individuals (≥65 years) presents considerable clinical difficulties. Age-associated physiological alterations, frequent multimorbidity, and atypical symptom manifestations complicate the diagnostic process. The conventional fixed FEV₁/FVC threshold of <0.70 may not be optimally suited for this population. This study aimed to construct and validate a novel multidimensional diagnostic tool that integrates both clinical and functional parameters. Methods: We conducted a single-center retrospective diagnostic accuracy study involving 976 symptomatic elderly patients (mean age 73.0 ± 6.7 years) who underwent comprehensive post-bronchodilator spirometry between February 2023 and March 2025. A blinded multidisciplinary expert panel established final diagnoses (moderate/severe COPD versus non-COPD) based on GOLD 2023 criteria and comprehensive clinical assessment. Using a temporal split approach, patients were allocated to either a Derivation Cohort ( Results: The ECDS incorporates five weighted components: (100 - FEV₁/FVC), age >65 years, Charlson Comorbidity Index, mMRC dyspnea scale score, and COPD Assessment Test score. In the Derivation Cohort, the ECDS demonstrated excellent discriminative ability with an AUC of 0.972 (95% CI: 0.962-0.982), significantly outperforming FEV₁/FVC alone (AUC 0.942, Conclusion: The Elderly COPD Diagnostic Score (ECDS), which synthesizes spirometric data, clinical parameters, and comorbidity information, demonstrated excellent and validated diagnostic accuracy for moderate-to-severe COPD in elderly patients, surpassing the performance of conventional FEV₁/FVC criteria. Implementation of age-specific spirometric thresholds further refines diagnostic precision. The ECDS represents a practical, superior tool for diagnosing COPD in the complex geriatric patient population. While the ECDS offers a superior diagnostic tool for moderate-to-severe COPD in older adults, its performance in mild disease requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.